RNAI

[eagerlearner]

Melf, that's good to know it's still on short term bullish trend come next week.

Thanks a lot for the updates! 

[tommyt]

Congrats to all. I finally got my exit between 2.75-2.90. It took forever. I wish everyone a good weekend, and I hope RNAI may provide additional profits. The only caution I would make is concerning volume. I never had to wait this long to sell 10k. The buys and sells are small, so pace yourself. Thanks for everything.

[Melf Elf]

That was fun watching to final minute, to see if it would close above 2.70, the top of the channel.

The last prints looked like...2.71...2.71...2.70....2.71...2.73...2.73...2.74...2.74!!!

That's a breakout on a weekly closing basis, which could bring in some buying interest next week.

http://ts-lc.sc8.finance.lycos.com/1121455075718?User=demo&Pswd=demo&DataType=GIF&Symbol=NASDAQ:RNAI&Interval=5&Permission=1000&Ht=400&Wd=600&Display=2&Study=VOL&Param1=&Param2=&Param3=&FontSize=10&LocaleID=0x0409

Promising results in the treatment of Hepatitis B brought in some buying interest today, too.  RNAI is on fire.  Up 37% to 3.61.

http://ts-lc.sc8.finance.lycos.com/1122317120453?User=demo&Pswd=demo&DataType=GIF&Symbol=NASDAQ:RNAI&Interval=60&Permission=1000&Ht=400&Wd=600&Display=2&Study=&Param1=&Param2=&Param3=&FontSize=10&LocaleID=0x0409

[ramlau]

I knew I had to buy this stock when CREDIT SUISSE FIRST BOSTON and others bought like crazy at the sub-$2 level earlier this month.

Would have been a 2-bagger already. 

Ram

[Melf Elf]

I knew I had to buy this stock when CREDIT SUISSE FIRST BOSTON and others bought like crazy at the sub-$2 level earlier this month.

Would have been a 2-bagger already.

Ram

Same here, Ram.    

I liked it when I heard an analyst back in March talk about this one and ALNY, both RNA stocks.  Couldn't find a pattern that I liked though. 

[setravis]

Won two patents today in UK, insiders buying, and way, way oversold. In @ 2.23.

Nice find Tommyt. Put on my watch list.
Good volume and price action today.
applaud   

Spooktacular....
I put on my watch.....but I didn't do any watching....    

52wk Range: 2.91 - 8.52
Volume: 14,923,382
Avg Vol (3m): 382,363

Technicals
Record Price High
Most Actives
Record Price Break Out
Gap Up
Percentage Gainer
Price Gainer

Last Price Quote is:
inf%above 13-day MA
inf%above 50-day MA
RS Rating: 99 

Fundamentals
Analyst Downgrade to Hold
Earnings Expected on Nov 13

Key Data:
Market Cap (M): $395.03 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Hold


Merck bought 'em

• Merck to Buy Biotech Firm for $1.1B
AP (Tue 2:56am)
• [$$] Merck Purchase of Sirna Boosts Efforts in Gene-Silencing Field
at The Wall Street Journal Online (Mon 11:18pm)
• Merck to Buy Biotech Firm for $1.1B
AP (Mon 9:54pm)
• Eye On Stocks For Tuesday, Oct. 31
at Forbes.com (Mon 7:10pm)
• Aftermarket Movers: Intevac, Sirna Soar
AP (Mon 7:04pm)
• Merck Makes $1 Billion Bet On Nobel-Winning Discovery
at Forbes.com (Mon 7:00pm)
• Merck to buy Sirna for $1.1 billion in cash
Reuters (Mon 6:41pm)
• Merck agrees to pay $1.1 bln for Sirna Therapeutics
at MarketWatch (Mon 6:09pm)
• Merck to buy Calif. biotech firm
bizjournals.com (Mon 5:36pm)
• Merck to buy S.F. biotech Sirna for $1.1B
bizjournals.com (Mon 5:36pm)

[setravis]

All the headlines link.... http://finance.yahoo.com/q/h?s=RNAI




AP
Sector Wrap: RNAi Developer Shares Surge
Tuesday October 31, 4:05 pm ET
By Damian Troise, AP Business Writer 
Companies Developing RNAi-Based Drugs Gain on Merck Buyout of Sirna Therapeutics


NEW YORK (AP) -- Merck & Co.'s move to pay a headturning $1.1 billion for Sirna Therapeutics Inc. sent shares of several other small biotechnology companies skyrocketing Tuesday.
The biotechnology sector has seen a burst of M&A activity over the past several months and analysts expect the trend to continue, as big pharmaceutical companies look to fill their pipelines by acquiring smaller biotech operations. But the move to buy Sirna reinforces confidence in what many in the medical field see as the next stage in medical science -- the ability to click off specific genes that cause disease.


"We view this acquisition as a cornerstone technology for Merck," said Cantor Fitgerald analyst Pamela Bassett, in a note to investors. "We expect other companies with important breakthrough technology platforms that can be widely leveraged across multiple products and industries to be increasingly sought after by pharma."

Several other companies, including Alnylam Pharmaceuticals Inc. and CytRx Corp., are also developing drugs based on RNA interference technology, or gene silencing. The discoverers of the technique, Andrew Fire and Craig Mello, received the Nobel Prize for medicine for their find. Simply put, the technology focuses on shutting down specific genes by interfering with messenger-carrying RNA. Possibilities, which several companies are banking on, include the ability to target genes for chronic diseases, including cancer, and turn them off, eventually making broad approach treatments like chemotherapy unnecessary.

Shares of San Francisco-based Sirna nearly doubled on Merck's announcement to end at $12.63 on the Nasdaq, up $6.18. And Cambridge, Mass.-based Alnylam caught a $3.12, or 18.8 percent, boost, to end at $19.72, as analysts see the company as the next possible buyout target.

Shares of Los Angeles-based CytRx rose 28 cents, or 21.4 percent, to finish at $1.59.

Bassett said the acquisition price for Sirna fairly reflects its development-stage value. But with investor focus shifting to Alnylam as the next acquisition target, she maintained a "Hold" rating, citing a collaboration between Merck and Alnylam that is no longer relevant to Alnylam's future. And while she said there is speculation Novartis may buy out the company, there doesn't seem to be good reason until the company provides proof of technology.

Novartis is one of several development partners working with Alnylam.

But Bank of America analyst David Witzke raised his price target on Alnylam to $30 from $23, and maintained a "Buy" rating, citing the company's position as "the only major stand-alone siRNA discovery platform" after the Merck buyout of Sirna.

"Alnylam has filed over 200 patents and patent applications for fundamental RNAi structure and uses," he wrote in a note to clients.

The deal between Merck and Sirna will likely not impact Merck's obligations under a collaboration agreement with Alnylam to develop age-related blindness treatments, he said.

Rodman & Renshaw analyst Michael G. King Jr. said the move by Merck validates the potential for the new technology, and notes that with "Sirna gone, Alnylam is the only game in town."

The company has taken steps to ensure its position as a leader in the field, he wrote, running a variety of clinical programs and employing a strong staff of scientists. King maintains a "Market Outperform" rating on the stock and said he is reviewing his current $18 price target.